Clostridium butyricum capsules, Live

ApprovedSmall molecule

TThe Affiliated Hospital of Qingdao University

Clostridium butyricum capsules, Live is one of 10 small molecule programs targeting Colorectal Adenoma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal AdenomaActive, not recruiting

Colorectal AdenomaApproved

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Colorectal Adenoma

#DrugCompanyPhaseTrials

Linzess

AbbVie

Approved

1 2

Lialda

Bayer Aspirin

2 4

Celebrex

PPhiladelphia Eye Associates

Phase 2

1 5

Glucophage

Boehringer Ingelheim

Phase 2

1 6

Berberine Hydrochloride

XXijing Hospital of Digestive Diseases

Phase 3

2 7

Clostridium butyricum capsules, Live

TThe Affiliated Hospital of Qingdao University

Approved

1 8

Mesalazine

Ferring

Phase 2

1 9

Acetylsalicylic Acid Lysinate

MMedical University of Vienna

Phase 3

1 10

Berberine

XXijing Hospital of Digestive Diseases

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Post-ApprovalNot yet recruiting

Colorectal Adenoma

NCT07167342

Clinical

Trials by Indication[1]

Colorectal Adenoma1 trial

The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma

Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 4·NCT07167342·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Clostridium butyricum capsules, Live. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clostridium butyricum capsules, Live compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clostridium butyricum capsules, Live. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Hospital of Qingdao University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe Affiliated Hospital of Qingdao University

Clostridium butyricum capsules, Live

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Colorectal Adenoma1 trial

References

Drug Info

Quick Facts

Related News